Seawolf Therapeutics launched with $100 million in Series A funding and a Sanofi deal worth up to $1.2 billion to develop treatments for bleeding disorders and other conditions. Seawolf could receive milestone payments and royalties, and expects to select a drug candidate by late 2027.
Seawolf Therapeutics launched with $100 million in Series A funding and a deal with Sanofi worth up to $1.2 billion. The companies will develop treatments for bleeding disorders and other undisclosed conditions; Seawolf could receive milestone payments and royalties. The agreement includes an upfront payment, CEO Elizabeth Alcamo said, but she declined to disclose its amount.
Seawolf’s TRIDENT technology uses tiny fat particles to carry DNA into cell nuclei without viruses. Its lead program, tested only in animals, aims to build muscle and reduce fat and could be used for obesity, muscle loss and osteoporosis. The company expects to pick a drug candidate by late 2027 and file to begin human trials by the end of 2028, but Alcamo said it will probably need additional capital to reach that stage.